Vincent C. Njar
Affiliations: | Molecular Medicine | University of Maryland School of Medicine, Baltimore, MD, United States |
Area:
Pharmacology, Molecular Biology, Physiology BiologyGoogle:
"Vincent Njar"Parents
Sign in to add mentor| Cecil H. Robinson | grad student | Johns Hopkins Medical School (Chemistry Tree) | ||
| (visiting scientist) | ||||
Children
Sign in to add trainee| Jyoti B. Patel | grad student | 2005 | University of Maryland Medical School |
| Aakanksha Khandelwal | grad student | 2007 | University of Maryland Medical School |
| Robert D. Bruno | grad student | 2009 | University of Maryland Medical School |
| Abhijit M. Godbole | grad student | 2011 | University of Maryland Medical School |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Ramamurthy VP, Ramalingam S, Kwegyir-Afful AK, et al. (2017) Targeting of protein translation as a new treatment paradigm for prostate cancer. Current Opinion in Oncology |
| Kwegyir-Afful AK, Murigi FN, Purushottamachar P, et al. (2016) Galeterone and its analogs inhibit Mnk-eIF4E axis, synergize with gemcitabine, impede pancreatic cancer cell migration, invasion and proliferation and inhibit tumor growth in mice. Oncotarget |
| Kwegyir-Afful AK, Bruno RD, Purushottamachar P, et al. (2016) Galeterone and VNPT55 disrupts Mnk-eIF4E to inhibit prostate cancer cell migration and invasion. The Febs Journal |
| Senthilmurugan R, Ramamurthy VP, Njar VC. (2016) Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets. The Journal of Steroid Biochemistry and Molecular Biology |
| Purushottamachar P, Kwegyir-Afful AK, Martin MS, et al. (2016) Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate. Acs Medicinal Chemistry Letters. 7: 708-13 |
| Dransfield DT, Jacoby DB, Namdev N, et al. (2016) Galeterone to target proteasomal degradation of the androgen receptor in prostate tumor cells: A novel mechanism of action for treatment of AR-V7+ CRPC. Journal of Clinical Oncology. 34: e14092-e14092 |
| Njar V, Zoubeidi A, Corey E, et al. (2016) PD32-07 GALETERONE SHOWS ANTI-TUMOR ACTIVITY IN MULTIPLE PRE-CLINICAL MODELS THAT EXPRESS ANDROGEN RECEPTOR SPLICE VARIANTS, SUPPORTING CORRELATIVE PATIENT DATA SEEN IN ARMOR2 Journal of Urology. 195 |
| Kwegyir-Afful AK, Ramalingam S, Purushottamachar P, et al. (2015) Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo. Oncotarget. 6: 27440-60 |
| Liao Z, Gu L, Vergalli J, et al. (2015) Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia. Molecular Cancer Therapeutics |
| Mbatia HW, Ramalingam S, Ramamurthy VP, et al. (2015) Novel C-4 heteroaryl 13-cis-retinamide Mnk/AR degrading agents inhibit cell proliferation and migration and induce apoptosis in human breast and prostate cancer cells and suppress growth of MDA-MB-231 human breast and CWR22Rv1 human prostate tumor xenografts in mice. Journal of Medicinal Chemistry. 58: 1900-14 |